Year Founded
2009
Ownership
Public
Employees
~5000
Stage
Commercial
Modalities
Viral vector vaccineProtein therapeuticsVaccines (general)mRNA therapeutics

CanSino Biologics General Information

Multiple approved vaccines including COVID-19 vaccines (Convidecia, Convidecia Air), meningococcal vaccines (Menhycia, Menphecia), and Ebola vaccine (Ad5-EBOV). Active pipeline across multiple infectious diseases.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Tianjin,
China

Drug Pipeline

Menhycia
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CanSino Biologics's pipeline data

Book a demo

Key Partnerships

Bill & Melinda Gates Foundation, McMaster University, National Institutes of Biotechnology Malaysia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CanSino Biologics Funding

Deal TypeDateAmountStatusStage
Later Stage VCOct 9, 2024$17.0MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CanSino Biologics's complete valuation and funding history, request access »

CanSino Biologics Investors

Qiming Venture Partners Ltd.
Investor Type: Venture Capital
Holding: Minority
Zhong Ou Asset Management Co.
Investor Type: Venture Capital
Holding: Minority
China Southern Asset Management Co.
Investor Type: Venture Capital
Holding: Minority